Sumitomo Pharma Co., Ltd.
住友ファーマ株式会社
Valuation
Fundamental ratios for the latest reported period.
Ticker: 4506
FY2025 (Mar 2026) · IFRS · consolidated Source: filing S100YH3M
FY = fiscal year, named by the calendar year it starts in; the month in brackets is when it ends (FY2025 ends Mar 2026 for a March year-end). FY2025 (Mar 2026) runs Apr 1, 2025 – Mar 31, 2026.
| Gross margin | 56.7% |
|---|---|
| Operating margin | 23.7% |
| Net margin | 23.6% |
| Return on equity | 46.3%Includes one-off items (e.g. gains on negative goodwill) |
| Return on assets | 13.8% |
| Revenue growth (YoY) | 13.7% |
| EPS (basic) | ¥268.99 |
| EPS growth (YoY) | 352.2% |
| Current ratio | 1.03x |
| Equity ratio | 36.4% |
| Book value / share | ¥736.16 |
| Free cash flow | ¥64.4B |